This medicine is authorised for use in the European Union.


Jardiance is a medicine used to treat type 2 diabetes, chronic (long-term) heart failure and chronic kidney disease.

In type 2 diabetes, Jardiance is used in adults whose condition is not controlled well enough. It is used with appropriate diet and exercise in patients who cannot take metformin (another treatment for diabetes). It can also be used as an ‘add-on’ treatment to other diabetes medicines.
In chronic heart failure (a condition in which the heart does not pump blood around the body as well as it should), Jardiance is used in adults to treat symptoms of the disease. Jardiance is also used in adults with chronic kidney disease.

Jardiance contains the active substance empagliflozin.

This EPAR was last updated on 14/09/2023

Authorisation details

Product details
Agency product number
Active substance
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
  • Diabetes Mellitus, Type 2
  • Heart Failure
  • Renal Insufficiency, Chronic
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Boehringer Ingelheim International GmbH
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Binger Strasse 173
55216 Ingelheim

Product information

24/07/2023 Jardiance - EMEA/H/C/002677 - II/0074

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Drugs used in diabetes

Therapeutic indication

Type 2 diabetes mellitus

Jardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise

  • as monotherapy when metformin is considered 
  • in addition to other medicinal products for the treatment of diabetes

For study results with respect to combinations of therapies, effects on glycaemic control, and cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1. of the annex.

Heart failure

Jardiance is indicated in adults for the treatment of symptomatic chronic heart failure. 

Chronic kidney disease

Jardiance is indicated in adults for the treatment of chronic kidney disease.

Assessment history

Changes since initial authorisation of medicine

Related content

How useful was this page?

Add your rating
2 ratings
2 ratings